company background image
NTUS

Natus Medical NasdaqGS:NTUS Stock Report

Last Price

US$32.90

Market Cap

US$1.1b

7D

1.9%

1Y

25.4%

Updated

28 Jun, 2022

Data

Company Financials +
NTUS fundamental analysis
Snowflake Score
Valuation1/6
Future Growth3/6
Past Performance2/6
Financial Health6/6
Dividends0/6

NTUS Stock Overview

Natus Medical Incorporated provides medical device solutions focuses on the diagnosis and treatment of patients with central nervous and sensory system disorders worldwide.

Natus Medical Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Natus Medical
Historical stock prices
Current Share PriceUS$32.90
52 Week HighUS$33.93
52 Week LowUS$20.90
Beta0.24
1 Month Change0.21%
3 Month Change26.83%
1 Year Change25.43%
3 Year Change27.97%
5 Year Change-11.68%
Change since IPO127.68%

Recent News & Updates

Mar 04
Some Investors May Be Worried About Natus Medical's (NASDAQ:NTUS) Returns On Capital

Some Investors May Be Worried About Natus Medical's (NASDAQ:NTUS) Returns On Capital

What underlying fundamental trends can indicate that a company might be in decline? When we see a declining return on...

Shareholder Returns

NTUSUS Medical EquipmentUS Market
7D1.9%3.5%1.7%
1Y25.4%-25.7%-20.4%

Return vs Industry: NTUS exceeded the US Medical Equipment industry which returned -24% over the past year.

Return vs Market: NTUS exceeded the US Market which returned -18.8% over the past year.

Price Volatility

Is NTUS's price volatile compared to industry and market?
NTUS volatility
NTUS Average Weekly Movement8.8%
Medical Equipment Industry Average Movement10.4%
Market Average Movement8.0%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market3.2%

Stable Share Price: NTUS is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: NTUS's weekly volatility (9%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19871,400Tom Sullivanhttps://www.natus.com

Natus Medical Incorporated provides medical device solutions focuses on the diagnosis and treatment of patients with central nervous and sensory system disorders worldwide. It offers products and technologies used for the screening, detection, treatment, monitoring, and tracking of common medical ailments in newborn care, hearing impairment, neurological and neurosurgical treatments, epilepsy, sleep disorders, and neuromuscular diseases. The company also provides computerized neurodiagnostic systems for audiology, neurology, polysomnography, and neonatology; and software systems for managing and tracking disorders and diseases for public health laboratories.

Natus Medical Fundamentals Summary

How do Natus Medical's earnings and revenue compare to its market cap?
NTUS fundamental statistics
Market CapUS$1.13b
Earnings (TTM)US$12.68m
Revenue (TTM)US$478.30m

88.8x

P/E Ratio

2.4x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
NTUS income statement (TTM)
RevenueUS$478.30m
Cost of RevenueUS$199.61m
Gross ProfitUS$278.70m
Other ExpensesUS$266.01m
EarningsUS$12.68m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)0.37
Gross Margin58.27%
Net Profit Margin2.65%
Debt/Equity Ratio0%

How did NTUS perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is NTUS undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • PEG Ratio

Key Valuation Metric

Which metric is best to use when looking at relative valuation for NTUS?

Other financial metrics that can be useful for relative valuation.

NTUS key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue2.2x
Enterprise Value/EBITDA18.2x
PEG Ratio1.5x

Price to Earnings Ratio vs Peers

How does NTUS's PE Ratio compare to its peers?

NTUS PE Ratio vs Peers
The above table shows the PE ratio for NTUS vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average161.7x
LMDX LumiraDx
33.5x26.9%US$809.7m
VREX Varex Imaging
28.1x35.1%US$833.5m
LMAT LeMaitre Vascular
37.1x13.7%US$1.0b
MLAB Mesa Laboratories
548x53.9%US$1.1b
NTUS Natus Medical
88.8x58.9%US$1.1b

Price-To-Earnings vs Peers: NTUS is good value based on its Price-To-Earnings Ratio (88.8x) compared to the peer average (161.7x).


Price to Earnings Ratio vs Industry

How does NTUS's PE Ratio compare vs other companies in the US Medical Equipment Industry?

Price-To-Earnings vs Industry: NTUS is expensive based on its Price-To-Earnings Ratio (88.8x) compared to the US Medical Equipment industry average (34.5x)


Price to Earnings Ratio vs Fair Ratio

What is NTUS's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

NTUS PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio88.8x
Fair PE Ratio74.3x

Price-To-Earnings vs Fair Ratio: NTUS is expensive based on its Price-To-Earnings Ratio (88.8x) compared to the estimated Fair Price-To-Earnings Ratio (74.3x).


Share Price vs Fair Value

What is the Fair Price of NTUS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: NTUS ($32.9) is trading above our estimate of fair value ($19.19)

Significantly Below Fair Value: NTUS is trading above our estimate of fair value.


Price to Earnings Growth Ratio

PEG Ratio: NTUS is poor value based on its PEG Ratio (1.5x)


Discover undervalued companies

Future Growth

How is Natus Medical forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

Future Growth Score

3/6

Future Growth Score 3/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


58.9%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: NTUS's forecast earnings growth (58.9% per year) is above the savings rate (1.9%).

Earnings vs Market: NTUS's earnings (58.9% per year) are forecast to grow faster than the US market (13.8% per year).

High Growth Earnings: NTUS's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: NTUS's revenue (4.4% per year) is forecast to grow slower than the US market (8.3% per year).

High Growth Revenue: NTUS's revenue (4.4% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if NTUS's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Past Performance

How has Natus Medical performed over the past 5 years?

Past Performance Score

2/6

Past Performance Score 2/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


9.7%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: NTUS has a large one-off loss of $7.4M impacting its March 31 2022 financial results.

Growing Profit Margin: NTUS became profitable in the past.


Past Earnings Growth Analysis

Earnings Trend: NTUS's earnings have grown by 9.7% per year over the past 5 years.

Accelerating Growth: NTUS has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: NTUS has become profitable in the last year, making it difficult to compare its past year earnings growth to the Medical Equipment industry (12.9%).


Return on Equity

High ROE: NTUS's Return on Equity (2.9%) is considered low.


Discover strong past performing companies

Financial Health

How is Natus Medical's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: NTUS's short term assets ($286.8M) exceed its short term liabilities ($112.9M).

Long Term Liabilities: NTUS's short term assets ($286.8M) exceed its long term liabilities ($24.3M).


Debt to Equity History and Analysis

Debt Level: NTUS is debt free.

Reducing Debt: NTUS has no debt compared to 5 years ago when its debt to equity ratio was 35.5%.

Debt Coverage: NTUS has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: NTUS has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Discover healthy companies

Dividend

What is Natus Medical current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate NTUS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate NTUS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if NTUS's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if NTUS's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as NTUS has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

3.4yrs

Average management tenure


CEO

Tom Sullivan (57 yo)

0.50

Tenure

US$5,167,297

Compensation

Mr. Thomas Joseph Sullivan, also known as Tom, has been the Chief Executive Officer and President of Natus Medical Incorporated since December 27, 2021 and serves as its Director. Mr. Sullivan served as Pr...


CEO Compensation Analysis

Compensation vs Market: Tom's total compensation ($USD5.17M) is about average for companies of similar size in the US market ($USD4.00M).

Compensation vs Earnings: Tom's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: NTUS's management team is considered experienced (3.4 years average tenure).


Board Members

Experienced Board: NTUS's board of directors are considered experienced (3.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Natus Medical Incorporated's employee growth, exchange listings and data sources


Key Information

  • Name: Natus Medical Incorporated
  • Ticker: NTUS
  • Exchange: NasdaqGS
  • Founded: 1987
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Implied Market Cap: US$1.134b
  • Shares outstanding: 34.24m
  • Website: https://www.natus.com

Number of Employees


Location

  • Natus Medical Incorporated
  • 3150 Pleasant View Road
  • Middleton
  • Wisconsin
  • 53562
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/06/28 00:00
End of Day Share Price2022/06/28 00:00
Earnings2022/03/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.